Santhera Pharmaceuticals Holding AG Cash Flow Conversion Efficiency

Latest as of December 2025: 1.199x

Santhera Pharmaceuticals Holding AG cash flow conversion efficiency. Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) has a cash flow conversion efficiency ratio of 1.199x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-14.16 Million ≈ $-17.91 Million USD) by net assets (CHF-11.82 Million ≈ $-14.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Santhera Pharmaceuticals Holding AG (2006–2025)

Cash flow conversion efficiency of Santhera Pharmaceuticals Holding AG from 2006 to 2025. This chart illustrates how Santhera Pharmaceuticals Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SANN share price today for real-time trading data and today's change.

Santhera Pharmaceuticals Holding AG Cash Flow Conversion Ratio Explained

Santhera Pharmaceuticals Holding AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Santhera Pharmaceuticals Holding AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Santhera Pharmaceuticals Holding AG ranked by their cash flow conversion efficiency. Also see Santhera Pharmaceuticals Holding AG market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Perma-Pipe International Holdings Inc NASDAQ:PPIH	0.065x
CammSys Corp KQ:050110	0.258x
Evolution Global Acquisition Corp Class A Ordinary Shares NASDAQ:EVOX	0.003x
H+H International A/S CO:HH	0.054x
GSR IV Acquisition Corp. Class A ordinary share NASDAQ:GSRF	-0.001x
Infinity Natural Resources, Inc. NYSE:INR	-0.084x
Iljin HySolus Co Ltd KO:271940	0.006x
Transgene SA PA:TNG	-0.152x

Annual Cash Flow Conversion Efficiency for Santhera Pharmaceuticals Holding AG (2006–2025)

The table below shows the annual cash flow conversion efficiency of Santhera Pharmaceuticals Holding AG from 2006 to 2025. Review Santhera Pharmaceuticals Holding AG free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CHF-11.82 Million ≈ $-14.94 Million	CHF-34.76 Million ≈ $-43.95 Million	2.942x	+329.37%
2024-12-31	CHF27.70 Million ≈ $35.02 Million	CHF-35.53 Million ≈ $-44.92 Million	-1.283x	-262.65%
2023-12-31	CHF59.94 Million ≈ $75.78 Million	CHF47.27 Million ≈ $59.76 Million	0.789x	+15.44%
2022-12-31	CHF-43.69 Million ≈ $-55.23 Million	CHF-29.84 Million ≈ $-37.73 Million	0.683x	+102.43%
2021-12-31	CHF1.33 Million ≈ $1.68 Million	CHF-37.36 Million ≈ $-47.23 Million	-28.132x	-510.82%
2020-12-31	CHF-6.35 Million ≈ $-8.03 Million	CHF-43.51 Million ≈ $-55.01 Million	6.848x	+5506.63%
2019-12-31	CHF21.25 Million ≈ $26.86 Million	CHF2.60 Million ≈ $3.28 Million	0.122x	+108.98%
2018-12-31	CHF27.83 Million ≈ $35.18 Million	CHF-37.87 Million ≈ $-47.87 Million	-1.361x	-10.74%
2017-12-31	CHF32.26 Million ≈ $40.78 Million	CHF-39.63 Million ≈ $-50.11 Million	-1.229x	-236.64%
2016-12-31	CHF74.35 Million ≈ $94.00 Million	CHF-27.14 Million ≈ $-34.31 Million	-0.365x	-73.20%
2015-12-31	CHF106.25 Million ≈ $134.32 Million	CHF-22.39 Million ≈ $-28.31 Million	-0.211x	+40.08%
2014-12-31	CHF17.24 Million ≈ $21.79 Million	CHF-6.06 Million ≈ $-7.67 Million	-0.352x	+64.17%
2013-12-31	CHF7.11 Million ≈ $8.98 Million	CHF-6.98 Million ≈ $-8.82 Million	-0.982x	-4.32%
2012-12-31	CHF11.73 Million ≈ $14.83 Million	CHF-11.04 Million ≈ $-13.96 Million	-0.941x	-103.34%
2011-12-31	CHF42.98 Million ≈ $54.34 Million	CHF-19.89 Million ≈ $-25.15 Million	-0.463x	-385.61%
2010-12-31	CHF69.63 Million ≈ $88.03 Million	CHF-6.64 Million ≈ $-8.39 Million	-0.095x	+61.65%
2009-12-31	CHF83.51 Million ≈ $105.58 Million	CHF-20.75 Million ≈ $-26.24 Million	-0.249x	+43.18%
2008-12-31	CHF104.47 Million ≈ $132.08 Million	CHF-45.69 Million ≈ $-57.77 Million	-0.437x	-164.92%
2007-12-31	CHF135.51 Million ≈ $171.33 Million	CHF-22.37 Million ≈ $-28.28 Million	-0.165x	-1.08%
2006-12-31	CHF152.05 Million ≈ $192.23 Million	CHF-24.83 Million ≈ $-31.40 Million	-0.163x	--

About Santhera Pharmaceuticals Holding AG

SW:SANN Switzerland Biotechnology

Market Cap

$270.39 Million

CHF213.87 Million CHF

Market Cap Rank

#15569 Global

#169 in Switzerland

Share Price

CHF15.04

Change (1 day)

-1.83%

52-Week Range

CHF10.20 - CHF18.54

All Time High

CHF1070.00